Paula Stanley
Family · Bonifay, FLNPI 1669984654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$486
- AstraZeneca$447
- Lilly USA, LLC$408
- Pfizer$295
- Amgen$288
- Grifols USA, LLC$284
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,25697%
- Education$1293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $486 |
| AstraZeneca | 28 | $447 |
| Lilly USA, LLC | 27 | $408 |
| Pfizer | 16 | $295 |
| Amgen | 19 | $288 |
| Grifols USA, LLC | 17 | $284 |
| Merck | 14 | $264 |
| Teva Pharmaceuticals USA, Inc. | 5 | $215 |
| Otsuka America Pharmaceutical, Inc. | 11 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $190 |
| Novartis | 10 | $174 |
| Novo Nordisk | 7 | $125 |
| Bayer | 5 | $113 |
| Vifor Pharma, Inc. | 3 | $92 |
| CSL Behring | 4 | $77 |
| GSK | 5 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Astellas Pharma US Inc | 3 | $64 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Biogen | 2 | $35 |
| Eisai Inc. | 2 | $34 |
| Dexcom, Inc. | 1 | $30 |
| Exact Sciences | 2 | $28 |
| GRT US Holding, Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $26 |
| Sanofi | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Insmed, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$4,385 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 31 | $425,672 |
| EliquisApixaban | 177 | $122,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $108,667 |
| VraylarCariprazine Hcl | 46 | $67,046 |
| FarxigaDapagliflozin Propanediol | 78 | $51,353 |
| TrulicityDulaglutide | 50 | $48,577 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $47,393 |
| EntrestoSacubitril/Valsartan | 64 | $46,138 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $45,204 |
| MounjaroTirzepatide | 36 | $38,532 |
| OzempicSemaglutide | 34 | $36,868 |
| XareltoRivaroxaban | 42 | $32,501 |
| MyrbetriqMirabegron | 36 | $26,055 |
| LinzessLinaclotide | 40 | $25,783 |
| Lurasidone Hcl | 46 | $24,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $284 | $425,67231 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $295 | $149,049201 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $76 | $135,865173 claims |
| AbbVieVraylar, Linzess | $486 | $92,82986 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $408 | $87,10986 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $447 | $73,640155 claims |
| NovartisEntresto | $174 | $46,13864 claims |
| Novo NordiskOzempic | $125 | $36,86834 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $19 | $34,38056 claims |
| MerckJanumet, Januvia | $264 | $32,72148 claims |
| Johnson & JohnsonXarelto | $21 | $32,50142 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $26,05536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Bonifay
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.